Strategies to Mitigate the Rising Cancer Cost Burden



Cheryl Allen, BSPharm, MBA, Vice President of Industry Relations at Diplomat Pharmacy, discusses the increasing cost burden of cancer therapies and future strategies for mitigating costs. 

Transcript

If you’re looking at it from a payer’s perspective, we see payers really paying a lot of attention to the oncology space, particularly self-administered oncology, looking at the criteria of use for those. You look at CML. Now we have patients who are living longer. This has become a chronic disease for these patients. So we see some specialty generics coming to space, imatinib for CML. You see some benefits across the entire space with overall cost of therapy with these specialty generics.



Related Articles

The presence of human papillomavirus type 16 antibodies marked an approximately 100-fold increase in risk of throat cancer in white individuals.
Colon cancer may spread to other parts of the body before original tumors are clinically detectable.
Top news of the day from across the health care landscape.
Company Profile >
Industry Guide >
Market News >
Peer Exchange >
Conferences >
Subscribe >
Specialty Times Resources
About Us
Advertise
Careers
Contact Us
Terms & Conditions
Privacy
MJH Associates >
Pharmacy Times
OTCGuide
American Journal of Managed Care
Cure
MD Magazine
ONCLive
Targeted Oncology
Physicians' Education Resource
Pharmacy & Healthcare Communications, LLC
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 609-716-7777
F: 609-716-4747

Copyright Specialty Pharmacy Times 2006-2019
Pharmacy & Healthcare Communications, LLC. All Rights Reserved.
 

$vacMongoViewPlus$